CTI BioPharma (CTIC) Receives a Buy from Brookline Capital Markets

Brookline Capital Markets analyst Leah R. Cann maintained a Buy rating on CTI BioPharma (CTICResearch Report) yesterday and set a price target of $12.00. The company’s shares closed yesterday at $5.92.

According to TipRanks, R. Cann is an analyst with an average return of -3.7% and a 36.68% success rate. R. Cann covers the Healthcare sector, focusing on stocks such as Moderna, Syros Pharmaceuticals, and Kymera Therapeutics.

CTI BioPharma has an analyst consensus of Strong Buy, with a price target consensus of $10.15.

See the top stocks recommended by analysts >>

CTIC market cap is currently $660M and has a P/E ratio of -4.75.

Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is neutral on the stock. Last month, Bvf Partners LP Il, a Director at CTIC sold 7,210,566.00 shares for a total of $44,128,663.92.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CTI BioPharma Corp. operates as a biopharmaceutical company, which focuses on the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. Its products include PIXUVRI, Pacritinib, Tosedostat and Opaxio. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.

Read More on CTIC:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More